arGEN-X appoints Alain Thibault CMO
This article was originally published in Scrip
Preclinical-stage antibody company arGEN-X has appointed Dr Alain Thibault chief medical officer. Prior to joining arGEN-X, Dr Thibault was therapeutic area head of oncology at Regeneron Pharmaceuticals, and his previous career included senior research positions at Johnson & Johnson and Roche. In addition, arGEN-X has appointed Dr Jacobus Rasser, previously senior partner at IP law firm Howrey, IP counsel.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.